Authors
Dermime, SaidGilham, David E
Shaw, David M
Davidson, Emma J
Meziane, El-Kahina
Armstrong, Anne C
Hawkins, Robert E
Stern, Peter L
Affiliation
Immunology, Cancer Research UK Groups, Paterson Institute for Cancer Research and University of Manchester, Christie Hospital NHS Trust, Manchester M20 4BX, UK.Issue Date
2004-07-06
Metadata
Show full item recordAbstract
Clearer evidence for immune surveillance in malignancy and the identification of many new tumour-associated antigens (TAAs) have driven novel vaccine and antibody-targeted responses for therapy in cancer. The exploitation of active immunisation may be particularly favourable for TAA where tolerance is incomplete but passive immunisation may offer an additional strategy where the immune repertoire is affected by either tolerance or immune suppression. This review will consider how to utilise both active and passive types of therapy delivered by T cells in the context of the failure of tumour-specific immunity by presenting cancer patients. This article will outline the progress, problems and prospects of several different vaccine and antibody-targeted approaches for immunotherapy of cancer where proof of principle pre-clinical studies have been or will soon be translated into the clinic. Two examples of vaccination-based therapies where both T cell- and antibody-mediated anti-tumour responses are likely to be relevant and two examples of oncofoetal antigen-specific antibody-directed T cell therapies are described in the following sections: (1) therapeutic vaccination against human papillomavirus (HPV) antigens in cervical neoplasia; (2) B cell lymphoma vaccines including against immunoglobulin idiotype; (3) oncofoetal antigens as tumour targets for redirecting T cells with antibody strategies.Citation
Vaccine and antibody-directed T cell tumour immunotherapy. 2004, 1704 (1):11-35 Biochim. Biophys. ActaJournal
Biochimica et Biophysica ActaDOI
10.1016/j.bbcan.2004.03.002PubMed ID
15238242Type
ArticleLanguage
enISSN
0006-3002ae974a485f413a2113503eed53cd6c53
10.1016/j.bbcan.2004.03.002